METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

References

Page 1

	Year	Citations
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Journal of Clinical Oncology	2001	997
Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Jennifer R. Grandis, D J Tweardy PubMed Neck CancerPathologyGrowth Factor AlphaDermatologyCancer Biology	1993	859
BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. PubMed	2025	844
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Denis Soulières, Neil Senzer, Everett E. Vokes, Journal of Clinical Oncology	2003	803
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer Roy S. Herbst, David H. Johnson, Eric D. Mininberg, Journal of Clinical Oncology	2005	535
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Valerie W. Rusch, José Baselga, Carlos Cordon‐Cardo, PubMed Lung InflammationPathologyPrimary NsclcGrowth Factor AlphaCancer Biology	1993	488
Epidermal growth factor receptor tyrosine kinase Walter H.J. Ward, Peter N. Cook, Anthony M. Slater, Biochemical Pharmacology Signal TransductionReceptor Tyrosine KinaseMedicineCell BiologyCell Signaling	1994	261
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Shazli N. Malik, Lillian L. Siu, Eric K. Rowinsky, PubMed	2003	130
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man D. McKillop, Michael G. Hutchison, E. A. Partridge, Xenobiotica PathologyPharmacotherapyAlpha-1 Acid GlycoproteinOxidative StressGastrointestinal Peptide Hormone	2004	130
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva) Manuel Hidalgo, Duane C. Bloedow Seminars in Oncology Clinical PotentialMedicineClinical PharmacologyPharmacotherapyPharmacology	2003	96

Page 1